Tag:

health insurance

Health

To lower drug prices, give PBMs a fiduciary duty to patients

by Chief Editor
written by Chief Editor

The Shifting Landscape of Pharmacy Benefit Managers: Accountability and Transparency on the Horizon

For years, concerns have mounted regarding the role of pharmacy benefit managers (PBMs) in the prescription drug supply chain. Accusations of prioritizing profits over patient access and affordability have been widespread. Now, a confluence of Congressional action and Department of Labor (DOL) initiatives signals a potential turning point, aiming to align PBM incentives with those of employers and patients.

The PBM Model Under Scrutiny

PBMs act as intermediaries between health insurers, employers, and pharmaceutical companies. They negotiate drug prices, create formularies (lists of covered drugs), and process claims. However, the complexity of these arrangements has often lacked transparency, leading to questions about how rebates and discounts are utilized.

Research indicates that while PBMs negotiate, the benefits haven’t consistently translated to savings for payers or patients. A study highlighted that PBMs’ share of insulin expenditures nearly tripled between 2014 and 2018 without corresponding overall savings. Increased rebates have been linked to higher list prices, ultimately increasing out-of-pocket costs for individuals whose cost-sharing is tied to those list prices.

Recent Legislative and Regulatory Developments

The enactment of the Inflation Reduction Act of 2022 authorized the federal government to negotiate lower drug prices with manufacturers for some drugs covered by Medicare. More recently, the Consolidated Appropriations Act (CAA) mandated a broad framework for PBM transparency, making them the most transparent actor in the prescription drug supply chain.

Building on this momentum, in January 2026, the Department of Labor proposed a rule focused on improving transparency into PBM fee disclosure. This proposal aims to shed light on PBM practices and ensure fair pricing. However, the Pharmaceutical Care Management Association (PCMA) has urged the DOL to rescind the proposed rule, arguing it duplicates requirements already established in the CAA and imposes unnecessary burdens.

What’s Next for PBMs? Potential Future Trends

Several key trends are likely to shape the future of PBMs:

  • Increased Fiduciary Responsibility: A significant shift is the potential for PBMs to be held legally accountable as fiduciaries. This would require them to act in the best interests of their clients (employers and health plans) and beneficiaries (patients).
  • Enhanced Transparency: The CAA and the DOL’s proposed rule (despite challenges to its implementation) are driving a demand for greater transparency in PBM operations. Expect more detailed reporting on fees, rebates, and spread pricing (the difference between what a PBM pays a pharmacy and what it bills the health plan).
  • Rise of Pass-Through PBMs: A growing number of employers are opting for “pass-through” PBM arrangements, where all rebates and discounts are directly passed on to the plan sponsor, eliminating potential conflicts of interest.
  • Vertical Integration Challenges: The trend of PBMs acquiring or partnering with pharmacies and other healthcare providers will likely face increased scrutiny to ensure fair competition and prevent anti-competitive practices.

Impact on Patients and Employers

These changes have the potential to deliver significant benefits:

  • Lower Drug Costs: Increased transparency and negotiation power could lead to lower net drug costs for employers and patients.
  • Improved Access to Medications: More equitable formulary design and reduced administrative burdens could improve patient access to necessary medications.
  • Greater Plan Sponsor Control: Employers and health plans will have more insight into PBM operations and greater control over their pharmacy benefits.

FAQ

  • What is spread pricing? Spread pricing is the difference between what a PBM pays a pharmacy for a drug and what it bills the health plan.
  • What does it mean for PBMs to be fiduciaries? It means they are legally obligated to act in the best interests of their clients and beneficiaries.
  • Will these changes immediately lower my prescription drug costs? The impact will likely be gradual as new regulations are implemented and contracts are renegotiated.

Pro Tip: Employers should actively review their PBM contracts and consider requesting a full audit of PBM performance to ensure they are receiving the best possible value.

Did you realize? The Department of Labor’s proposed rule follows a similar approach to state-level PBM regulations already in place in several states.

Stay informed about the evolving landscape of pharmacy benefit management and advocate for policies that prioritize affordability and access to essential medications. Explore additional resources on the Department of Labor’s Employee Benefits Security Administration (EBSA) website for the latest updates and guidance.

0 comments
0 FacebookTwitterPinterestEmail
Health

Early adulthood hypertension linked to heart and kidney disease later in life

by Chief Editor
written by Chief Editor

The Silent Threat: How Young Adult Blood Pressure Shapes Lifelong Heart and Kidney Health

New research presented at the American Heart Association’s EPI|Lifestyle Scientific Sessions 2026 reveals a concerning link between blood pressure levels in young adulthood and the risk of developing heart and kidney disease later in life. The findings underscore the critical importance of proactive blood pressure management, even when short-term risks appear low.

The Long Game: Cumulative Blood Pressure and Future Disease Risk

For years, the focus has been on managing blood pressure in middle age and beyond. However, this study, analyzing data from nearly 300,000 adults in South Korea, demonstrates that the cumulative effect of elevated blood pressure during the formative years of 30 to 40 can significantly increase the likelihood of heart disease, stroke, and kidney disease after age 40.

Researchers found that even a relatively small increase in blood pressure – around 10 mm Hg higher than peers for a decade – was associated with a 27% higher risk of heart disease. Similarly, a 5 mm Hg increase in diastolic pressure over 10 years correlated with a 20% increased risk. Those with the highest cumulative blood pressure levels during young adulthood were 3.5 times more likely to develop heart conditions and 3 times more likely to experience kidney disease in midlife.

Why Early Blood Pressure Matters – Even with Low Short-Term Risk

“Young adults often have a very low predicted 10-year risk of heart disease, even when they have elevated or high blood pressure,” explains Dr. Hokyou Lee of Yonsei University College of Medicine. “Our study’s findings show that blood pressure levels in early adulthood are key even if short-term risk appears low. Long-term exposure to higher blood pressure from early life may accumulate damage over time.”

This accumulation of damage highlights a crucial point: cardiovascular health isn’t solely about immediate risk factors. It’s about the long-term impact of lifestyle choices and physiological conditions.

The AHA’s Evolving Guidelines and the Focus on Early Intervention

The American Heart Association recognizes the importance of early intervention. Their 2025 High Blood Pressure Guideline recommends treatment for stage 1 hypertension, even in adults with a low predicted 10-year risk, after a period of lifestyle modification. This shift reflects a growing understanding of the long-term consequences of untreated hypertension.

Dr. Daniel W. Jones, a volunteer expert with the AHA, emphasizes the value of this research. “This study from Korea emphasizes the risk from high blood pressure begins at an early age and early in the course,” he stated. “The opportunity in this study to evaluate cumulative blood pressure over several years was important in understanding that risk.”

The Role of Universal Healthcare and Future Research

The study’s data originated from the Korean National Health Insurance Service, a universal healthcare system. This standardized approach to healthcare, with consistent screening and treatment protocols, provided a robust dataset for analysis. The researchers suggest that further randomized clinical trials are needed to definitively prove that early treatment of high blood pressure in young adults effectively reduces the risk of cardiovascular and kidney disease.

What Does This Mean for You?

Maintaining optimal blood pressure is a lifelong commitment. Early prevention, diagnosis, and treatment, if needed, are essential investments in future health. Regular health screenings, a healthy diet, regular exercise, and stress management are all crucial components of a heart-healthy lifestyle.

Frequently Asked Questions

  • What is considered high blood pressure? A systolic blood pressure of 120 mm Hg or higher, or a diastolic blood pressure of 80 mm Hg or higher, is generally considered high blood pressure.
  • Is high blood pressure reversible? Lifestyle changes and medication can effectively manage and often lower blood pressure.
  • How often should I get my blood pressure checked? At least once a year, or more frequently if you have risk factors for high blood pressure.
  • What are the symptoms of high blood pressure? High blood pressure often has no symptoms, which is why regular screening is so important.

Pro Tip: Preserve a blood pressure log and share it with your doctor during your annual check-up. This provides valuable data for tracking your cardiovascular health.

Want to learn more about protecting your heart health? Explore our articles on healthy eating for a strong heart and the benefits of regular exercise.

Did you know? Nearly half of U.S. Adults are living with high blood pressure, making it the leading cause of cardiovascular disease and premature death.

Share your thoughts! What steps are you taking to manage your blood pressure? Leave a comment below.

0 comments
0 FacebookTwitterPinterestEmail
Health

Medicare Advantage Auto-Enrollment Under Review by CMS | STAT+

by Chief Editor
written by Chief Editor

The Future of Medicare: Automatic Enrollment and the Rise of Managed Care

The debate over the future of Medicare is intensifying, with a potential shift towards automatic enrollment in Medicare Advantage plans gaining traction. Chris Klomp, President Trump’s Medicare director, recently revealed that the Centers for Medicare & Medicaid Services (CMS) is exploring the feasibility of automatically enrolling beneficiaries in either Medicare Advantage or accountable care organizations (ACOs). Currently, those who don’t actively choose a plan default to traditional Medicare.

What’s Driving the Push for Automatic Enrollment?

The core argument behind automatic enrollment centers on fostering stronger, more proactive healthcare relationships. Klomp suggests that a default enrollment in a managed care setting could lead to “a long-term, secular relationship between the beneficiary, the patient, and their provider.” This contrasts with the current system, where individuals may not actively engage with their healthcare until a need arises.

This consideration aligns with ideas presented in the conservative Project 2025 policy blueprint, signaling a potential broader ideological push towards managed care within Medicare. The goal is to move beyond a fee-for-service model and incentivize preventative care and coordinated health management.

Medicare Advantage: A Growing Force

Medicare Advantage plans, offered by private insurers, are already a significant part of the Medicare landscape. They often include extra benefits not covered by traditional Medicare, such as vision, dental, and hearing care. However, concerns exist regarding potential limitations in provider networks and prior authorization requirements.

The potential for automatic enrollment could dramatically increase the number of beneficiaries in Medicare Advantage. This would have significant implications for insurers, providers, and beneficiaries alike. UnitedHealth, a major player in the Medicare Advantage market, is already facing challenges as it enters 2026 with a smaller business, indicating a complex and evolving market.

Challenges and Concerns Remain

Whereas proponents argue automatic enrollment could improve care coordination and outcomes, critics raise concerns about limiting beneficiary choice. Individuals would still have the option to opt out, but the default setting could disproportionately affect those who are less informed or engaged in their healthcare decisions.

Recent regulatory changes have also highlighted ongoing scrutiny of Medicare Advantage plans. A federal judge recently vacated a rule that would have increased audits of these plans, potentially impacting oversight and accountability. CMS has delayed a rule requiring insurers to remind members of unused benefits, raising questions about ensuring beneficiaries fully utilize their coverage.

The Role of Accountable Care Organizations (ACOs)

Alongside Medicare Advantage, ACOs represent another potential default enrollment option. ACOs are groups of doctors, hospitals, and other healthcare providers who voluntarily work together to deliver coordinated, high-quality care to their Medicare patients. The Medicare Shared Savings Program incentivizes ACOs to reduce healthcare costs while improving patient outcomes.

Choosing ACOs as a default option could emphasize care coordination and preventative services, potentially aligning with the goals of improving long-term health management.

Frequently Asked Questions

What is Medicare Advantage? Medicare Advantage plans are offered by private companies approved by Medicare. They provide all Medicare Part A and Part B benefits and often include extra benefits.

What is an Accountable Care Organization (ACO)? An ACO is a group of doctors, hospitals, and other healthcare providers who voluntarily work together to deliver coordinated care to Medicare patients.

Would I be able to switch back to traditional Medicare if automatically enrolled? Yes, individuals would still have the option to opt out of the automatically assigned plan and choose a different Medicare arrangement.

What is Project 2025? Project 2025 is a conservative policy blueprint outlining a vision for the next presidential administration, including proposals related to healthcare reform.

What does it mean if CMS delays a rule? A delay means the rule will not be implemented on the originally scheduled date, giving stakeholders more time to prepare or allowing CMS to reconsider the policy.

Did you know? Enrollment in Medicare Advantage plans has been steadily increasing over the past decade, now covering over half of all Medicare beneficiaries.

Pro Tip: Regularly review your Medicare options during the annual enrollment period to ensure you have the coverage that best meets your needs.

Stay informed about the evolving landscape of Medicare. Explore CMS.gov for official updates and resources.

0 comments
0 FacebookTwitterPinterestEmail
Health

Prudential Paid Out RM1m In Medical Claims To A Policyholder In 2025

by Chief Editor
written by Chief Editor

Malaysia’s Healthcare Costs Are Soaring: What Does This Mean for Your Insurance?

Kuala Lumpur – A recent case highlighted by Prudential Assurance Malaysia Berhad (PAMB) underscores a growing trend: medical costs are escalating rapidly. In 2025, PAMB paid out over RM1 million in claims for a single policyholder undergoing breast cancer treatment, a figure that reflects both advances in oncology and the increasing complexity – and cost – of care.

The RM1 Million Claim: A Sign of the Times

The policyholder, a senior citizen, required multiple surgeries, a prolonged ICU stay, and advanced cancer therapies. This isn’t an isolated incident. PAMB’s highest individual medical claim in 2024 reached RM732,000, and the company saw its total medical claim payouts double from RM1 billion in 2022 to RM2 billion in 2024. This surge is driven by higher healthcare utilization and increasingly complex treatments.

Why Are Costs Rising?

PAMB attributes the increase to several factors, including greater access to advanced medical capabilities in Malaysia and the inherent complexity of treating serious illnesses. The company points out that annual limits of RM50,000 or RM100,000, common in 2013, are now often insufficient, particularly when considering post-hospitalisation care and potential multiple admissions.

The Debate Over Annual Limits

This observation puts PAMB at odds with Bank Negara Malaysia (BNM), which proposes a base medical insurance product with annual limits of RM100,000 (under 60s) and RM150,000 (over 60s). BNM argues this is sufficient for 99% of treatment episodes. Yet, PAMB’s claims experience suggests otherwise. The company declined to share detailed claims statistics but emphasized that premiums are determined by actuarial pricing based on claims experience, medical inflation, and policyholder health status.

Who is Most Affected?

PAMB data reveals that policyholders aged 60 and above incur the highest medical claim payouts. Women account for 52% of medical claims, with common conditions including heart disease, breast cancer, cataracts, pneumonia, and gastritis.

Transparency and Responsible Sales Practices

PAMB stresses the importance of clear communication regarding policy terms, exclusions, and pre-existing conditions. All agents undergo mandatory training and assessments to ensure they can adequately explain coverage details to customers. The company also provides structured sales tools, including medical disclosure guides, to support this process.

The Future of Medical Insurance

The trends are clear: medical costs are rising, and adequate insurance coverage is becoming increasingly crucial. The debate surrounding annual limits highlights the need for a balance between affordability and comprehensive protection. As the Base MHIT framework is reviewed, it remains to be seen how it will address the concerns raised by insurers like PAMB regarding the adequacy of coverage for complex and costly treatments.

Frequently Asked Questions

  • What is the Base MHIT? It’s a proposed base medical and health insurance/takaful product by Bank Negara Malaysia.
  • Are pre-existing conditions covered under the Base MHIT? Health Minister Dzulkefly Ahmad announced the Base MHIT will cover pre-existing conditions, but details are still emerging.
  • Why are medical costs increasing? PAMB attributes it to higher healthcare utilization and increasing treatment complexity.
  • Is a RM100,000 annual limit sufficient? PAMB believes it is often inadequate, particularly for serious illnesses requiring prolonged or complex treatment.

Pro Tip: Don’t wait until you need it. Review your medical insurance coverage regularly and ensure it aligns with your current and future healthcare needs.

What are your thoughts on the rising cost of healthcare and its impact on insurance? Share your experiences in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Access to weight-loss meds must be expanded

by Chief Editor
written by Chief Editor

The GLP-1 Revolution: How New Drugs Are Reshaping Obesity Treatment and Healthcare

For decades, public health campaigns have focused on diet and exercise to combat rising obesity rates. Despite these efforts, obesity continued to climb, reaching 40% of Americans in 2022. Now, a new class of medications – GLP-1 receptor agonists – is offering a dramatically different outcome.

Beyond Diet and Exercise: The Power of GLP-1s

Medications like semaglutide and tirzepatide are demonstrating unprecedented success in weight loss, helping patients lose 15% to 20% of their body weight. This level of sustained weight loss has historically been unattainable through behavioral interventions alone.

GLP-1s aren’t just about shedding pounds. Research indicates they can significantly improve overall health. A study by the University of Southern California’s Schaeffer Center for Health Policy & Economics suggests that young adults (ages 25-34) starting GLP-1 treatment could gain nearly two years of life expectancy, and experience six fewer years with diabetes. Even older adults (65-74) could see a six-month increase in life expectancy, alongside reductions in diabetes duration.

The Economic Impact: A Trillion-Dollar Opportunity

The potential benefits extend far beyond individual health. Widespread access to GLP-1 therapies could generate nearly $1 trillion in cumulative social benefits over the next decade. Medicare alone could save between $175 billion and $245 billion in the first 10 years, largely due to reduced hospitalizations and nursing home care.

This isn’t just about cost savings; it’s about improving quality of life. GLP-1s have the potential to dramatically reduce health disparities, as obesity disproportionately affects Black and Hispanic Americans (53% and 43% respectively).

The impact mirrors that of beta blockers, which, after their approval in 1976, led to equal reductions in hypertension and cardiac disease across income levels. GLP-1s could bridge a similar gap for obesity, offering a biological solution where behavioral interventions have fallen short.

Accessibility and Affordability: Breaking Down Barriers

Despite the promising results, access to GLP-1s remains limited. Currently, fewer than one-third of insurers cover these medications for weight loss, and cash-paying patients often can’t apply those costs toward their deductibles.

Yet, the cost barrier is beginning to crumble. Injectable prices have fallen by 50% or more, and a new once-a-day GLP-1 pill is available with a starter price of $149 per month, potentially attracting a wider range of patients.

A Paradigm Shift in Obesity Treatment

The conversation around obesity is evolving. Just as diabetes came to be understood as a biological disease treatable with insulin, there’s a growing recognition that obesity requires a similar approach. GLP-1s represent a significant step toward this paradigm shift.

Did you know?

Celebrities like Serena Williams, Oprah Winfrey, Kathy Bates, and Whoopi Goldberg have publicly discussed using GLP-1 receptor agonists for weight loss, bringing increased attention to these medications.

FAQ

Q: What are GLP-1s?
A: GLP-1s are glucagon-like peptide-1 receptor agonists, a class of medications that help with weight loss and improve metabolic health.

Q: How much weight loss can I expect with GLP-1s?
A: Patients typically experience 15% to 20% body weight loss.

Q: Are GLP-1s covered by insurance?
A: Coverage varies, but currently, fewer than one-third of insurers cover GLP-1s for weight loss.

Q: What are the potential long-term health benefits of GLP-1s?
A: Potential benefits include increased life expectancy, reduced risk of diabetes, hypertension, heart disease, stroke, and cancer.

Pro Tip: Discuss GLP-1s with your healthcare provider to determine if they are a suitable treatment option for you, considering your individual health profile and insurance coverage.

Explore more articles on health policy and economics here.

0 comments
0 FacebookTwitterPinterestEmail
Health

Medicare Advantage: $76B Surplus & Industry Pushback on Oversight

by Chief Editor
written by Chief Editor

Medicare Advantage: A $76 Billion Surplus and a Looming Political Battle

The federal government is on track to spend 14% more to cover individuals enrolled in Medicare Advantage (MA) plans compared to those in traditional Medicare – a staggering $76 billion surplus directed towards health insurance companies, according to a recent report by the Medicare Payment Advisory Commission (MedPAC).

The Growing Gap in Payments

This significant financial disparity highlights a long-standing issue: consistent overpayments to MA insurers. MedPAC, an independent body advising Congress on Medicare, has repeatedly pointed out these overpayments. The current $76 billion figure represents a substantial increase, fueling debate about the program’s financial sustainability and fairness.

Industry Pushback and Lobbying Efforts

As scrutiny intensifies, industry groups are actively working to counter MedPAC’s findings and influence policy decisions. Organizations like the Better Medicare Alliance and the Healthcare Leadership Council have criticized MedPAC’s reports and are advocating for increased funding for the program. Their efforts include endorsing editorials questioning MedPAC’s credibility and supporting legislation that could limit the commission’s research capabilities.

The Trump Administration’s Role and Future Outlook

The future of Medicare Advantage funding is closely tied to the current political landscape. The article suggests a potentially favorable environment for MA insurers under the Trump administration, mirroring a trend observed during his first term. Previous administrations, including the Biden administration, have also increased payments to MA plans, though subsequently attempted to address overpayments and care denials.

Coding Practices and Revenue Impacts

Recent government proposals to maintain relatively flat payments for MA plans next year, coupled with changes to coding practices, have caught the health insurance industry off guard. These changes, particularly those addressing “upcoding” – a practice where insurers inflate risk scores to justify higher payments – could significantly impact insurer revenue.

Providers Exiting Medicare Advantage Networks

Concerns about inadequate provider networks are growing, with healthcare providers increasingly leaving MA plans. This trend, alongside plans scaling back benefits and withdrawing from certain areas, raises questions about the long-term viability and quality of care offered through Medicare Advantage.

What is Project 2025 and How Could it Impact Medicare Advantage?

A policy proposal known as Project 2025 aims to build Medicare Advantage the default enrollment option in Medicare and significantly reduce oversight of the program. If implemented, this could accelerate the privatization of Medicare and potentially exacerbate existing overpayment issues.

Did you know?

The Medicare Advantage program is expected to cost taxpayers and beneficiaries over $500 billion this year.

FAQ: Medicare Advantage Overpayments

  • What is Medicare Advantage? Medicare Advantage offers a way to get your Medicare Part A and Part B benefits through a private insurance company.
  • Why are there overpayments to MA plans? Overpayments are attributed to factors like risk adjustment inaccuracies and coding practices.
  • What is MedPAC? The Medicare Payment Advisory Commission is an independent group that advises Congress on Medicare policy.
  • What is upcoding? Upcoding is the practice of inflating risk scores to receive higher payments from Medicare.

Pro Tip: Beneficiaries should carefully compare coverage options and provider networks before enrolling in a Medicare Advantage plan.

Explore more articles on Health Care Inc. to stay informed about the latest developments in Medicare policy.

Have questions about Medicare Advantage? Share your thoughts in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

High medical debt leads to significant delays in routine and preventive care

by Chief Editor
written by Chief Editor

Medical Debt’s Growing Shadow: How Delayed Care Impacts Americans

Medical debt is a pervasive issue in the United States, and a new study from the Johns Hopkins Bloomberg School of Public Health reveals a troubling connection: financial hardship directly leads to people delaying essential healthcare. This isn’t limited to major procedures; the research shows significant deferrals in dental, medical, and mental health services, even among those with health insurance.

The Scale of the Problem: A Nation Postponing Treatment

The study, published in the Journal of General Internal Medicine on March 10, analyzed data from the 2023 National Health Interview Survey, encompassing nearly 30,000 U.S. Adults. Over 10% of participants reported struggling with medical debt – defined as difficulty paying medical bills in the past year. But the numbers truly highlight the impact on access to care.

Individuals burdened by medical debt were found to be 2.4 times more likely to postpone dental care, 4.3 times more likely to delay medical care, and nearly three times more likely to put off mental healthcare compared to those without debt. Specifically, 42.3% with medical debt delayed dental care, 23.0% delayed medical care, and 14% delayed mental health care.

Dental Care: The Most Vulnerable Service

The research indicates that dental care is particularly susceptible to being deferred due to financial constraints. This may be since dental insurance is often separate from medical insurance, and typically offers more limited coverage. The consequences of delaying dental care extend beyond oral health, with links to heart disease and cognitive decline.

Pro Tip: Explore community dental clinics and dental schools for lower-cost options if you’re facing financial barriers to dental care.

Insurance Status Matters, But Doesn’t Eliminate the Risk

Whereas the impact of medical debt on deferred care was consistent across insurance types, the study found a significant difference between insured and uninsured adults. Uninsured individuals experiencing medical debt were considerably more likely to delay medical care than those with commercial insurance. Specifically, 32.5% of uninsured adults with medical debt deferred medical care, compared to 16.9% of those with commercial insurance.

The prevalence of medical debt itself varies by insurance status: 19.5% among the uninsured, 12.6% with Medicaid, 9.3% with commercial insurance, and 8.1% with Medicare.

The Ripple Effect: Worsening Health and Economic Strain

Delaying care doesn’t just impact individual health; it creates a cycle of worsening conditions and increased costs. As Catherine Ettman, PhD, a senior author of the study, explains, “Avoiding routine or preventative care can worsen patient health conditions, ultimately making them more costly to address—for patients, insurers, and taxpayers.”

Did you realize? Preventive care, like regular check-ups and screenings, can often identify and address health issues before they become serious and expensive to treat.

Policy Implications and Future Concerns

The study’s authors emphasize that recent policy changes, such as potential cuts to insurance coverage, could exacerbate the problem of medical debt and deferred care. They advocate for policies that address affordability and mitigate the financial burden of medical expenses.

FAQ: Medical Debt and Access to Care

  • What is considered medical debt? Medical debt is defined as experiencing problems paying or being unable to pay medical bills, including those for doctors, dentists, hospitals, and medication.
  • Does having health insurance protect me from medical debt? While insurance helps, it doesn’t eliminate the risk. The study shows that even insured individuals can experience medical debt and delay care.
  • Which type of care is most often delayed due to medical debt? Dental care is the most commonly deferred service, likely due to limited or separate dental insurance coverage.
  • What can be done to address this issue? Policies that improve affordability and reduce the financial burden of medical expenses are crucial.

This research underscores the urgent need for comprehensive solutions to address medical debt and ensure equitable access to healthcare for all Americans. Further investigation is needed to fully understand the long-term consequences of deferred care and to develop effective strategies for prevention and intervention.

Explore further: Read more about the financial burden of healthcare on The Roosevelt Institute’s analysis of the US medical debt crisis.

0 comments
0 FacebookTwitterPinterestEmail
Health

Health insurance startup Alan reaches €5B valuation

by Chief Editor
written by Chief Editor

Alan’s €5 Billion Valuation: A Sign of Health Tech Resilience?

Despite a challenging environment for European startups, French health insurance company Alan has secured a €5 billion (approximately $5.83 billion) valuation. This achievement, up from $4.5 billion in 2024, signals potential resilience within the health tech sector and offers insights into evolving investor priorities.

The European Unicorn Landscape

Recent data suggests a downturn for European unicorns, with approximately 30% potentially losing their billion-dollar status. Alan’s success stands in stark contrast, demonstrating that strong fundamentals and a clear path to growth can still attract significant investment. This divergence highlights a growing selectivity among investors, favoring companies demonstrating profitability or a clear route to it.

Alan’s Growth Trajectory

Founded in 2016, Alan now serves one million employees, freelancers, and retirees. The company’s app provides a comprehensive suite of services, including reimbursement management, doctor access, and health habit tracking. A recent €100 million ($116 million) funding round, led by Index Ventures with participation from Greenoaks, Kaaf, SH, Belfius, Shopify founder Tobi Lütke, and Antoine Griezmann, fuels its expansion plans.

Expanding Market Reach and Revenue Growth

Alan’s growth isn’t limited to its home market. The company has secured contracts to provide health insurance to 135,000 French civil servants and has expanded into Belgium, Spain, and Canada. In 2025, Alan reported €785 million ($915 million) in annual recurring revenue (ARR), a 53% increase from 2024. The company is approaching operational break-even, having halved its losses as a percentage of revenue over the past year, despite previous net losses of $61 million in 2023 and $56 million in 2024.

The Role of AI and Strategic Partnerships

Alan’s CEO, Jean-Charles Samuelian-Werve, as well holds a position at Mistral AI, a French AI company. This connection underscores Alan’s commitment to leveraging artificial intelligence to enhance its services. The company intends to “invest ambitiously, particularly in [tech] and [AI].” Strategic partnerships, such as the ongoing collaboration with Belfius, are also crucial to Alan’s continued success.

Future Focus: ARR Growth Over Immediate Profitability

While nearing operational break-even, Alan is prioritizing ARR growth, aiming for $1.16 billion in 2026. This strategy suggests a willingness to forgo immediate profitability in favor of long-term market dominance and continued innovation. Investors appear to support this approach, recognizing the potential for substantial returns in the rapidly evolving health tech landscape.

Pro Tip

For startups seeking funding in a challenging economic climate, Alan’s success demonstrates the importance of demonstrating strong revenue growth, a clear path to profitability, and a commitment to innovation.

FAQ

Q: What is Alan’s current valuation?
A: €5 billion (approximately $5.83 billion).

Q: Where does Alan currently operate?
A: France, Belgium, Spain, and Canada.

Q: What is Alan’s annual recurring revenue (ARR)?
A: €785 million (approximately $915 million) as of 2025.

Q: Is Alan profitable?
A: Alan is approaching operational break-even and has significantly reduced its losses.

Q: Who are some of Alan’s investors?
A: Index Ventures, Greenoaks, Kaaf, SH, Belfius, Tobi Lütke, and Antoine Griezmann.

Did you know? Alan was the first new independent insurance company to receive a license in France since the 1980s.

Want to learn more about the future of health tech? Explore our other articles or subscribe to our newsletter for the latest insights.

0 comments
0 FacebookTwitterPinterestEmail
Health

Oregon’s Corporate Medicine Ban Tested in Hospital Dispute | STAT News

by Chief Editor
written by Chief Editor

The Growing Conflict Between Corporate Medicine and Independent Practice

The healthcare landscape is witnessing a renewed clash between large hospital systems and independent physician groups, exemplified by a current battle in Oregon. This dispute, as reported by Tara Bannow, centers on the state’s recently revised ban on corporate medicine – a law designed to protect physician autonomy and patient care from undue corporate influence.

What is Corporate Medicine?

Corporate medicine refers to the practice of healthcare where medical decisions are influenced by financial considerations and business objectives of a corporation, rather than solely by the best interests of the patient. This can manifest in various ways, including hospital systems employing physicians and dictating treatment protocols, or corporations directly owning and operating medical practices.

Oregon’s Ban and the Current Challenge

Oregon’s updated ban aims to prevent hospitals from interfering with a physician’s medical judgment. The current case involves a local physician group challenging PeaceHealth, a large hospital system, over the replacement of emergency room doctors with ApolloMD. The core of the dispute revolves around whether PeaceHealth’s actions violate the spirit and letter of the corporate medicine ban.

The Broader Trend: Consolidation and its Discontents

The Oregon case isn’t isolated. It reflects a national trend of hospital consolidation, where larger systems acquire smaller practices and hospitals. While proponents argue this leads to economies of scale and improved efficiency, critics, like Bob Herman, point to potential downsides, including reduced competition, higher prices, and a shift in focus from patient care to profit maximization.

This consolidation often leads to increased administrative burdens for physicians, less control over treatment decisions, and a potential decline in the quality of care. The pressure to meet financial targets can incentivize hospitals to prioritize profitable services over those that are medically necessary but less lucrative.

The Rise of Private Equity in Healthcare

Adding another layer of complexity is the growing involvement of private equity firms in healthcare. These firms often acquire physician practices and hospitals, implementing cost-cutting measures and streamlining operations to maximize returns. This can lead to staffing shortages, reduced investment in infrastructure, and a focus on short-term profits over long-term patient care.

The Impact on Patients

The consequences of corporate influence in medicine extend directly to patients. Increased costs, limited access to care, and a perceived erosion of the doctor-patient relationship are all potential outcomes. The UnitedHealth expose, detailed by Herman and Ross, revealed tactics used to deny care to patients in Medicare Advantage plans, highlighting the potential for profit motives to override medical necessity.

Patients may find themselves facing higher deductibles, co-pays, and out-of-pocket expenses. They may also experience difficulty finding physicians who are willing to accept their insurance or who have the time to provide comprehensive care.

Looking Ahead: Potential Future Trends

Several trends are likely to shape the future of this conflict:

  • Increased Scrutiny: Expect greater scrutiny of hospital mergers and acquisitions, as well as the role of private equity in healthcare.
  • State-Level Legislation: More states may consider enacting or strengthening bans on corporate medicine to protect physician autonomy and patient care.
  • Direct Primary Care: The growth of direct primary care (DPC) models, where patients pay a monthly fee directly to their physician, could offer an alternative to traditional insurance-based care and reduce corporate influence.
  • Telehealth Expansion: Telehealth could potentially increase access to care, but also raises questions about the role of corporate providers in virtual care settings.

FAQ

What is the goal of a corporate medicine ban?

To protect physician independence and ensure medical decisions are made in the best interest of the patient, not driven by corporate profits.

How does hospital consolidation affect patients?

It can lead to higher costs, reduced access to care, and a potential decline in the quality of care.

What is direct primary care?

A healthcare model where patients pay a monthly fee directly to their physician, bypassing traditional insurance.

Is private equity involvement in healthcare increasing?

Yes, private equity firms are increasingly acquiring physician practices and hospitals.

Where can I learn more about Bob Herman’s reporting?

You can find Bob Herman’s work at STAT News and sign up for his Health Care Inc. Newsletter.

Did you know? The UnitedHealth strategy revealed by STAT involved using a computer algorithm to pressure medical staff to cut off payments for seriously ill patients.

Pro Tip: When choosing a healthcare provider, ask about their ownership structure and whether they are affiliated with a large hospital system.

What are your thoughts on the increasing corporate influence in healthcare? Share your experiences and opinions in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Heterogeneous associations of a mobile health-based disease management program on uncontrolled hypertension: A target trial emulation study

by Chief Editor
written by Chief Editor

Mobile Health: A Personalized Path to Better Blood Pressure Control

A recent study published in PLOS Digital Health highlights the growing potential of mobile health (mHealth) interventions in managing hypertension. Researchers found that a mobile app-based program, combined with remote coaching, led to a 5% reduction in participants with uncontrolled hypertension over one year. But the real story isn’t just that it worked, but for whom it worked best.

The Rise of Personalized mHealth

Hypertension remains a significant global health challenge, and traditional management often struggles with patient adherence. MHealth solutions – encompassing smartphone apps, wearables, and remote monitoring – are increasingly seen as a way to bridge this gap. The market for these apps is booming, with a projected CAGR of 15.6% according to Market.us.

This latest research emphasizes that a “one-size-fits-all” approach isn’t effective. Individuals who were already motivated to improve their lifestyle, had higher diastolic blood pressure at the start, and demonstrated consistent daily habits benefited the most from the program. This suggests that tailoring interventions to individual readiness and needs is crucial.

Beyond the App: The Power of Coaching

The study’s mHealth program, “Mystar,” wasn’t just about tracking data. It included 12 phone calls with healthcare professionals and ongoing chat support. This human element appears to be vital. The program targeted key lifestyle factors – exercise, diet, sleep, and stress – providing personalized guidance. This mirrors successful hypertension management programs in Japan, which are integrated into the country’s universal health coverage system.

Identifying Who Benefits Most

Researchers used advanced analytical techniques, including the G-formula and SuperLearner algorithms, to identify key factors influencing program success. Interestingly, age played a smaller role than modifiable behaviors. Individuals with an intermediate level of health awareness – those already making some healthy choices but with room for improvement – showed the greatest gains. This suggests that mHealth interventions can be particularly effective for those on the cusp of change.

Conversely, the study identified a group who showed limited responsiveness. These individuals may require more intensive, multimodal support beyond app-based coaching, potentially including in-person consultations and more comprehensive lifestyle interventions.

Future Trends in Digital Hypertension Management

The findings point towards several key trends in the future of digital hypertension management:

  • Hyper-Personalization: Expect to observe apps that dynamically adjust their recommendations based on real-time data and individual responses.
  • AI-Powered Coaching: Artificial intelligence could play a larger role in providing personalized support and motivation.
  • Integration with Wearables: Seamless integration with wearable devices will provide a more comprehensive picture of a patient’s health.
  • Focus on Behavioral Economics: Interventions will increasingly leverage principles of behavioral economics to nudge users towards healthier choices.
  • Remote Patient Monitoring: Expanded use of remote monitoring will allow healthcare providers to intervene proactively when needed.

Singapore is already actively exploring these avenues, with initiatives focused on helping residents manage chronic diseases through digital health solutions.

The JSH Morning Hypertension Eradication Program

Related efforts, such as the JSH Morning Hypertension Eradication Program Project, demonstrate a continued focus on innovative approaches to blood pressure control. These programs highlight the importance of early detection and intervention.

FAQ

Q: Is mHealth right for everyone with hypertension?
A: Not necessarily. The research suggests it’s most effective for those already motivated to make lifestyle changes.

Q: What kind of data do these apps collect?
A: Typically, they track weight, activity levels, diet, and blood pressure readings.

Q: Is my data secure with these apps?
A: Data privacy is a key concern. Reputable apps will adhere to strict data security protocols and comply with relevant regulations.

Q: Can mHealth replace traditional medical care?
A: No. MHealth is best used as a complement to, not a replacement for, regular checkups and consultations with a healthcare professional.

Did you know? Individuals with higher diastolic blood pressure at the start of the program experienced greater benefits, suggesting mHealth interventions can be particularly impactful for those with more significant needs.

Pro Tip: Before starting any modern health program, consult with your doctor to ensure it’s appropriate for your individual needs.

Desire to learn more about managing your blood pressure? Explore additional resources on the American Heart Association website.

Share your thoughts! Have you used a mobile health app to manage your blood pressure? Let us know in the comments below.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts